187 related articles for article (PubMed ID: 30341231)
1. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis.
Sridharan K; Sivaramakrishnan G; Sequeira RP; Elamin A
Postgrad Med J; 2018 Oct; 94(1116):556-565. PubMed ID: 30341231
[TBL] [Abstract][Full Text] [Related]
2. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
Said A; Akhter A
Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.
Sawangjit R; Chongmelaxme B; Phisalprapa P; Saokaew S; Thakkinstian A; Kowdley KV; Chaiyakunapruk N
Medicine (Baltimore); 2016 Aug; 95(32):e4529. PubMed ID: 27512874
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
Tang JT; Mao YM
J Dig Dis; 2017 Nov; 18(11):607-617. PubMed ID: 29106066
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic landscape of non-alcoholic steatohepatitis.
Perazzo H; Dufour JF
Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Singh S; Khera R; Allen AM; Murad MH; Loomba R
Hepatology; 2015 Nov; 62(5):1417-32. PubMed ID: 26189925
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials.
Wang Y; Yi H; Sun W; Yu H; Tao W; Yu X; Jia D; Liu Y; Pandol SJ; Li L
Drugs; 2024 Apr; 84(4):425-439. PubMed ID: 38478331
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.
Eshraghian A
World J Gastroenterol; 2017 Nov; 23(42):7495-7504. PubMed ID: 29204050
[TBL] [Abstract][Full Text] [Related]
9. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.
Mahady SE; Webster AC; Walker S; Sanyal A; George J
J Hepatol; 2011 Dec; 55(6):1383-90. PubMed ID: 21703200
[TBL] [Abstract][Full Text] [Related]
10. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
12. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
Angelico F; Burattin M; Alessandri C; Del Ben M; Lirussi F
Cochrane Database Syst Rev; 2007 Jan; (1):CD005166. PubMed ID: 17253544
[TBL] [Abstract][Full Text] [Related]
13. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
Ganesh S; Rustgi VK
Clin Liver Dis; 2016 May; 20(2):351-64. PubMed ID: 27063274
[TBL] [Abstract][Full Text] [Related]
14. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
15. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Caldwell S
Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis.
Panunzi S; Maltese S; Verrastro O; Labbate L; De Gaetano A; Pompili M; Capristo E; Bornstein SR; Mingrone G
Diabetes Obes Metab; 2021 Apr; 23(4):980-990. PubMed ID: 33368954
[TBL] [Abstract][Full Text] [Related]
17. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
18. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials.
Amanullah I; Khan YH; Anwar I; Gulzar A; Mallhi TH; Raja AA
Postgrad Med J; 2019 Nov; 95(1129):601-611. PubMed ID: 31434683
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease: a systematic review.
Rinella ME
JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
[TBL] [Abstract][Full Text] [Related]
20. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]